BEAM$22.21
Chart
Performance
Key Stats
AI BEAM Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralThe company shows some positive fundamental indicators but faces significant challenges from its high valuation, negative earnings, and weak technicals. Thematic tailwinds are present but not strong enough to outweigh other concerns.
Thematic
Beam Therapeutics operates in the promising field of genetic medicine, with potential for significant impact on serious diseases. However, the company is still in the development phase with a long road to commercialization.
Fundamental
The company's financials are characterized by significant losses and negative earnings. While revenue is present, it is not yet sufficient to cover operating expenses, and the balance sheet shows a considerable cash burn.
Technical
The stock has experienced a significant price decline and is trading below key moving averages. Momentum indicators are mixed, but the overall trend and recent price action suggest weakness.
| Factor | Score |
|---|---|
| Gene Editing Technology Advancement | 75 |
| Biotechnology Sector Growth | 70 |
| Pipeline Progression | 60 |
| Partnerships and Collaborations | 70 |
| Regulatory Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 15 |
| Balance Sheet Health | 30 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 50 |
| Volume Confirmation | 30 |
| Support & Resistance | 40 |
| Short-term Performance | 25 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprise
In Q1 2025, the reported EPS was -1.09, exceeding the estimate of -1.20, indicating better-than-expected profitability for the period.
Sufficient Cash Reserves
As of Q4 2024, the company held 281,967,000 in cash equivalents, providing a buffer for operational needs and potential investments.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a net income of -376,742,000 in 2024Q4 and -132,527,000 in 2023Q4, indicating ongoing profitability challenges.
Negative Revenue Growth
Revenue for 2024Q4 was 30,067,000, a significant decrease from 377,709,000 in 2023Q4, indicating a sharp decline in sales.
Calendar
August 2025
5
Next Earnings Date
H: $-0.78
A: $-1.09
L: $-1.40
H: 25.00M
A: 13.29M
L: 7.47M
Profile
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Seasonals
Price Target
44.07 USD
The 39 analysts offering 1 year price forecasts for BEAM have a max estimate of 80.00 and a min estimate of 20.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Co-founded by Beam's co-founder (David Liu), developing closely related prime editing technology.
Weight: 97
Key collaboration partner with Beam for ex vivo gene editing programs, particularly for hemoglobinopathies.
Weight: 96
Key collaboration partner with Beam for in vivo base editing programs for rare diseases.
Weight: 95
Direct competitor in the CRISPR/gene editing space, developing similar gene-edited therapies.